Positive Trial Results for AstraZeneca's Imfinzi in Lung Cancer Treatment

In a recent Phase 3 trial, AstraZeneca's immunotherapy drug Imfinzi demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) among patients with limited-stage small cell lung cancer (LS-SCLC). The study, known as ADRIATIC, is the first global Phase III trial to show a notable survival benefit for this form of lung cancer when treated with immunotherapy. The trial involved 730 patients whose disease had not progressed following standard treatment with concurrent chemoradiotherapy (cCRT).

The findings indicated that Imfinzi, either as monotherapy or in combination with Imjudo, increased the time patients lived without disease progression and extended overall survival compared to placebo. This outcome marks a significant advancement for the treatment of LS-SCLC, a particularly aggressive form of lung cancer known for rapid progression and recurrence after initial response to therapy.

The safety profile of Imfinzi in the trial remained consistent with previously established data, with no new safety concerns identified. These results will be presented in detail at an upcoming medical meeting and are expected to be discussed with global regulatory authorities. Imfinzi is already approved for the treatment of extensive-stage SCLC in various regions, including the US, EU, Japan, and China.